SCHEMBL25544155

SCHEMBL25544155

Cc1cc(-c2c(C(C)C)c(N[C@H](CO)C(=O)O)nc3cc(O)ccc23)ccc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 1/20 0.35
TOP1 P11387 1/20 0.33
CYP2C9 P11712 2/20 0.33
APP P05067 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
KCNQ3 O43525 4/20 0.33
KCNQ2 O43526 4/20 0.33
TACR3 P29371 1/20 0.32
ESR1 P03372 2/20 0.32
ESR2 Q92731 2/20 0.32
BCL2L1 Q07817 1/20 0.32
MCL1 Q07820 1/20 0.32
PDE10A Q9Y233 1/20 0.32
PIP4K2A P48426 2/20 0.32
CYP2C8 P10632 1/20 0.32
HTR2B P41595 1/20 0.32
MDM2 Q00987 1/20 0.32
DRD1 P21728 1/20 0.32
GRIN2B Q13224 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23895820 1.00 TRPV3 (0.35) TRPV3TOP1CYP2C9APPCYP3A4
SCHEMBL28974972 0.89 PDE10A (0.37) TOP1CYP2C9APPCYP3A4CYP2C19
SCHEMBL25544154 0.89 PDE10A (0.37) TOP1CYP2C9APPCYP3A4CYP2C19
SCHEMBL23895822 0.89 PDE10A (0.37) TOP1CYP2C9APPCYP3A4CYP2C19
SCHEMBL23895814 0.89 LRRK2 (0.37) TOP1CYP2C9TACR3ESR1ESR2
SCHEMBL23896259 0.89 LRRK2 (0.37) TOP1CYP2C9TACR3ESR1ESR2
SCHEMBL23895813 0.89 LRRK2 (0.37) TOP1CYP2C9TACR3ESR1ESR2
SCHEMBL23896419 0.87 CTSA (0.35) TOP1KCNQ3KCNQ2MDM2GRIN2B
SCHEMBL23896415 0.87 CTSA (0.35) TOP1KCNQ3KCNQ2MDM2GRIN2B
SCHEMBL23896036 0.85 PDE10A (0.38) TRPV3TOP1CYP2C9APPCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 TRPV3 4856/4885TOP1 277/4885CYP2C9 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.